PCSK9 and familial hyperaldosteronism: Although PCSK9 inhibitors clearly have considerable potential as an alternative to apheresis in the treatment of patients with statin-refractory heterozygous FH, their usefulness in homozygous FH and in patients with raised Lp(a) levels is less obvious and in most instances, they will complement rather than replace lipoprotein apheresis.